Adaptive Biotechnologies Corporation (NASDAQ:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, will be included in more than 20 abstracts studying the use of Adaptive’s clonoSEQ® Assay for minimal residual disease (MRD) assessment at the American Society of Clinical Oncology (ASCO) Annual Meeting from June 4-8, and the European Hematology Association (EHA) Virtual Congress from June 9-17. clonoSEQ is the first and only U.S. Food and Drug Administration (FDA)-cleared assay for MRD assessment in chronic lymphocytic leukemia (CLL), multiple myeloma (MM) and B-cell acute lymphoblastic leukemia (B-ALL), and is widely available to clinicians and patients across the U.S.
The Week In Cannabis: An Earnings Avalanche, Biden’s Clemency Plans, Cuomo’s Resignation And More
Below is a recap of the main news related to the cannabis industry and markets for the week of August 13, 2021, which was marked by earnings reports out of many of the largest companies in the space – all details below.
